Valuation: Candel Therapeutics, Inc.

Market Cap 851M 737M 697M 631M 1.18B 81.62B 1.19B 8.32B 3.2B 41.39B 3.2B 3.13B 132B P/E 2026 *
-7.92x
P/E 2027 * -10.2x
Enterprise Value 851M 737M 697M 631M 1.18B 81.62B 1.19B 8.32B 3.2B 41.39B 3.2B 3.13B 132B EV / Sales 2026 *
-
EV / Sales 2027 * 19.6x
Free-Float
85.01%
Yield 2026 *
-
Yield 2027 * -
09-14 Candel Therapeutics Insider Sold Shares Worth $3,160,783, According to a Recent SEC Filing MT
09-10 Candel Therapeutics, Inc. Announces Appointment of Martine Zimmermann to Board of Directors, Effective September 8, 2026 CI
08-14 BofA Adjusts Price Target on Candel Therapeutics to $12 From $9 MT
08-13 Candel Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
08-13 Candel Therapeutics Q2 Loss Widens MT
08-13 Earnings Flash (CADL) Candel Therapeutics Posts Q2 Net Loss $0.52 a Share, vs. FactSet Est of $0.21 Loss MT
07-13 Stifel Nicolaus Initiates Coverage on Candel Therapeutics With Buy Rating, $22 Price Target MT
06-30 Candel Therapeutics Stock Gains on Launch of Phase 3 Trial for Lung-Cancer Drug DJ
06-30 Candel Therapeutics, Inc. Initiates Global Pivotal Phase 3 Aurora Trial Evaluating Aglatimagene Besadenovec In Advanced Non-Small Cell Lung Cancer Patients With Inadequate Response To Immune Checkpoint Inhibitors CI
06-25 Candel Therapeutics, Inc. Appoints Mark Sims as Chief Commercial Officer, Effective July 6, 2026 CI
06-22 Candel Therapeutics, Inc.(NasdaqGM:CADL) added to S&P Biotechnology Select Industry Index CI
06-02 Candel Therapeutics, Inc. Announces Publication in the Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (Can-2409) in Localized Prostate Cancer CI
05-21 Certain Warrants of Candel Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2026. CI

Last Transcript: Candel Therapeutics, Inc.

1 day+4.17%
1 week-11.75%
Current month-14.92%
1 month-5.12%
3 months+29.91%
6 months+138.12%
Current year+96.81%
1 week 9.86
Extreme 9.855
12.05
1 month 9.86
Extreme 9.855
14
Current year 4.44
Extreme 4.44
14
1 year 4.35
Extreme 4.35
14
3 years 0.66
Extreme 0.66
14.6
5 years 0.66
Extreme 0.66
14.6
10 years 0.66
Extreme 0.66
14.78
Manager TitleAgeSince
Chief Executive Officer 66 31/08/2020
Director of Finance/CFO 41 11/01/2024
Chief Tech/Sci/R&D Officer 57 11/09/2022
Director TitleAgeSince
Director/Board Member 80 31/08/2017
Director/Board Member 66 31/08/2020
Chairman 70 14/07/2021
Date Insider Type Main position Quantity % Market Cap. Importance
11/09/26 Sell

Chief Executive Officer

-59,379 0.0776%
08/09/26 Free

Director

64,000 0.0836%
17/08/26 Sell

Chief Technology Officer

-7,000 0.0096%
Change 5-day change 1-year change 3-year change Capi.($)
+4.17%-11.75%+129.28%+782.54% 817M
+0.56%-3.38%-1.83%+8.00% 45.63B
-0.12%-1.19%+343.42%+545.03% 43.96B
+1.51%+4.04%+45.01%+27.38% 43.73B
-2.07%-1.42%+4.28%+72.97% 40.23B
-0.73%-3.06%+9.63%+38.92% 31.86B
-9.49%-11.23% - - 17.4B
+4.21%+5.01%+24.99%+121.62% 16.62B
+1.83%+3.20%+16.49%+32.73% 14.46B
-0.08%-2.81%+79.24%+31.27% 13.04B
Average -0.02%-2.73%+72.28%+184.49% 26.77B
Weighted average by Cap. -0.32%-1.31%+76.91%+132.78%

Financials

2026 *2027 *
Net sales - 43.38M 37.58M 35.53M 32.17M 60.38M 4.16B 60.83M 424M 163M 2.11B 163M 159M 6.73B
Net income -101M -87.56M -82.8M -74.96M -141M -9.7B -142M -988M -380M -4.92B -380M -371M -15.68B -85.65M -74.19M -70.15M -63.51M -119M -8.22B -120M -837M -322M -4.17B -322M -315M -13.29B
Net Debt - -
Logo Candel Therapeutics, Inc.
Candel Therapeutics, Inc. is a BLA-ready clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic antitumor immune response to help patients fight cancer. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor.
Employees
55
Date Price Change Volume
15/09/26 US$11.12 +4.17% 1,065,381
14/09/26 US$10.68 +1.23% 940,804
11/09/26 US$10.55 -6.93% 3,596,201
10/09/26 US$11.33 -6.90% 1,952,924
09/09/26 US$12.17 -3.41% 661,253
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
11.12USD
Average target price
21.00USD
Spread / Average Target
+88.85%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CADL Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!